Actinium Pharmaceuticals, Inc. (ATNM): Capital Expenditures
$104.0K
Year ended 2025-12-31
-34.3%
3-year compound annual growth
-16.3%
5-year compound annual growth
+8.1%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $104.0K | +845.5% | 2026-03-30, From 2025-01-01 |
| 2024-12-31 | $11.0K | -92.8% | 2026-03-30, From 2024-01-01 |
| 2023-12-31 | $153.0K | -58.2% | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | $366.0K | +175.2% | 2024-03-29, From 2022-01-01 |
| 2021-12-31 | $133.0K | -47.4% | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | $253.0K | +295.3% | 2022-03-25, From 2020-01-01 |
| 2019-12-31 | $64.0K | -33.4% | 2021-03-31, From 2019-01-01 |
| 2018-12-31 | $96.1K | +288.4% | 2020-05-08, From 2018-01-01 |
| 2017-12-31 | $24.7K | -58.7% | 2019-03-15, From 2017-01-01 |
| 2016-12-31 | $60.0K | +25.5% | 2019-03-15, From 2016-01-01 |
| 2015-12-31 | $47.8K | -68.5% | 2018-03-16, From 2015-01-01 |
| 2014-12-31 | $151.7K | +814.2% | 2017-03-16, From 2014-01-01 |
| 2013-12-31 | $16.6K | +603.3% | 2016-03-11, From 2013-01-01 |
| 2012-12-31 | $2.4K | n/a | 2014-02-28, From 2012-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Actinium Pharmaceuticals, Inc. (ATNM) | 2025-12-31 | $104.0K | +845.5% |
| Incannex Healthcare Inc. (IXHL) | 2025-06-30 | $8.0K | -97.1% |
| iBio, Inc. (IBIO) | 2026-06-30 | $578.0K | n/m |
| Inovio Pharmaceuticals, Inc. (INO) | 2025-12-31 | $285.7K | -41.4% |
| Connect Biopharma Holdings Ltd (CNTB) | 2025-12-31 | $434.0K | -42.1% |
| Serina Therapeutics, Inc. (SER) | 2025-12-31 | $59.0K | +168.2% |
| HCW Biologics Inc. (HCWB) | 2025-12-31 | $0 | -100.0% |
| Lisata Therapeutics, Inc. (LSTA) | 2025-12-31 | $28.0K | n/a |
| Altimmune, Inc. (ALT) | 2025-12-31 | $11.0K | n/a |
Compare ATNM, IXHL, IBIO, INO side by side · Screen every company in Pharmaceutical Preparations ↗